

Request for Proposals (RFP): Janssen Biotech, Inc.

Funding is available to support innovative and interactive activities at the Digestive Disease Week 2025 meeting in San Diego, CA with an enduring component for medical education that is designed to inform healthcare providers about the **underlying inflammatory pathways in IBD**.

Grant Application Deadline: Thursday September 19th at 12pm Eastern Standard Time

Therapeutic Area: Inflammatory Bowel Disease

Treatment Focus: Overall learning objective will include education on the most recent IL-23 inhibitor with a focus on UC & CD objective endoscopic endpoints, and the correlation with CD64 expressing cells in the inflamed gut. This will include:

- Overview of the connection between CD64 and IL-23 in UC and CD including a review of the in-vitro and ex-vivo molecular attributes of different IL-23s (affinity, potency, and functional effects of CD-64 binding)
- Analyze the recently released UC and CD clinical data for objective endoscopic endpoints including any recent data vs STELARA
- Review early symptom response data in UC and in CD
- Highlight flexibility of SC/IV induction dosing and SC maintenance doses/intervals in IL-23 therapies

Delivery Format: Live CME Satellite Symposia at **DDW 2025 Congress** with an enduring

Target Audience: Gastroenterologists, trainees, advance practice providers, and other healthcare professionals

Timelines: Program Start Date: May 4th-6th, 2025

Funding Requirements: \$350K maximum- Sole-support program

Eligibility Criteria: CME/CE applicants must fall into one of the following categories with a bona fide interest in GI Immunology or other specialties involved in the management of relevant adverse events:
Academic institutions (medicine, pharmacy or nursing) Teaching hospitals
Medical societies
Professional associations
Government agencies
Medical education companies (accredited)

Submission Link: Submissions to Janssen Immunology can be completed online at: <https://www.janssen.com/us/grants-and-giving/educational-grants/immunology>

Special Note: For disease state Please select **Other- RFP 2025-02 DDW**

For any questions related to this RFP, please email sgallag3@its.jnj.com.
